RxDoctor Payments Data

Laxmi Koya, MD

Gastroenterology · Lewisville, TXNPI 1205883832

Payments from drug & device makers

$1,058in general payments, 2019–2025

Across 54 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$222
  • Madrigal Pharmaceuticals$195
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$194
  • Pfizer$87
  • QOL Medical, LLC$72
  • Takeda Pharmaceuticals U.S.A., Inc.$50
  • plus $238 from 12 others

What the payments were for

  • Consulting fees$81%
  • Food & beverage$1,03798%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,058 in reported general payments places this provider in the 25th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$131,942
Medicare patients
375
Services billed
1,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide136$146,032
ZenpepLipase/Protease/Amylase32$123,079
CreonLipase/Protease/Amylase23$76,692
MovantikNaloxegol Oxalate19$9,538
SutabSod Sulf/Pot Chloride/Mag Sulf44$7,170
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates79$4,329
Omeprazole177$2,516
Lactulose50$2,363
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl113$1,693
Mesalamine15$1,423
Dicyclomine Hcl114$1,228
Ondansetron OdtOndansetron62$1,217
Famotidine119$1,194
Pantoprazole Sodium169$1,094
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl58$849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$222$222,725159 claims
Aimmune Therapeutics, Inc.Zenpep$39$123,07932 claims
Redhill Biopharma Inc.Movantik$17$9,53819 claims
Braintree Laboratories, Inc.Sutab$14$7,17044 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Lewisville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →